Feds push big Medicare formulary

The federal government is pressing private insurers offering a new drug benefit to include a long list of pharmaceuticals to their formularies. The result will likely be a wider choice of drugs than what is now available to many people in a private health plan, and some insurers are beginning to worry that the government's insistence on a broad drug package may force the cost of the program out of control. The drug benefit was originally advertised at a cost of $395 billion over 10 years, which was later raised to $534 billion. The Congressional Budget Office later revised that figure upward after accounting for the administration's formulary requirements.

- read this article from The New York Times for more

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.